Institute for Wealth Management LLC. Purchases New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Institute for Wealth Management LLC. bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,110 shares of the specialty pharmaceutical company's stock, valued at approximately $260,000.

A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. Algert Global LLC purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $637,000. Creative Planning lifted its holdings in shares of Jazz Pharmaceuticals by 21.7% during the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company's stock valued at $408,000 after buying an additional 680 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $213,000. SG Americas Securities LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $752,000. Finally, GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after acquiring an additional 121 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

JAZZ stock traded down $0.34 during midday trading on Tuesday, hitting $121.63. The company's stock had a trading volume of 419,905 shares, compared to its average volume of 501,137. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a 50 day moving average of $122.69 and a two-hundred day moving average of $116.10. The firm has a market capitalization of $7.35 billion, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 0.90 and a beta of 0.56.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on JAZZ shares. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Piper Sandler restated an "overweight" rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company's stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,253 shares of company stock valued at $890,594. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.